Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of Iberdomide Powder in Healthy Adults
NCT05899738Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of iberdomide in systemic lupus erythematosus (SLE) and multiple myeloma (MM) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration and 1 more. Started May 2023; status: completed.
02
Drugs
iberdomide
03
Conditions
systemic lupus erythematosus (SLE)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05899738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05899738.